After ‘Most Difficult Part’ Of Opill Decision, FDA Expects Pre-Study Tests Of Self-Reporting Methods
Executive Summary
“Improbable results” in HRA’s actual use study data provide lesson for FDA and sponsors of future OTC switch applications on designing actual use studies, according to summary of agency’s review of HRA’s sNDA for the first US OTC oral contraceptive.